Latest filing published 02 Dec 2024 for Longboard Pharmaceuticals, Inc., €1.7M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -10.6%Entry US$7.83 · Close at T+365 US$7.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Randall Kaye: trading record in brief
Randall Kaye is a declared insider at 3 companies; the most frequent names are Avanir Pharmaceuticals, Longboard Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. Over a trading history stretching from 8 May 2006 to 2 December 2024, the count stands at 57 filings.
On the open market, the record shows 9 purchases worth €37k and 19 sales worth €2.5M. Taken together, the sales exceed the purchases by €2.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 22 share grants and 5 option exercises. 2024 to date brings 1 purchase and 8 sales.
A typical purchase (the median) is worth €1,943.
On 2 December 2024 came the latest disclosure, a transaction for €1.7M in Longboard Pharmaceuticals, Inc. The most recent open-market purchase was published on 13 August 2024, 818 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Randall Kaye
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 30,554 shares@ US$60.0085.0% of flowCommon StockSEC:0001415889-24-028023:0
- 30,554 shares@ US$6.008.5% of flowCommon StockSEC:0000950170-24-128962:0
- 16,667 shares@ US$59.0422.5% of flowCommon StockSEC:0000950170-24-115026:1
- 16,667 shares@ US$4.353.3% of flowCommon StockSEC:0000950170-24-115026:0
- 9,366 shares@ US$30.896.5% of flowCommon StockSEC:0000950170-24-106949:1
- 4,200 shares@ US$31.813.0% of flowCommon StockSEC:0000950170-24-106949:2
- 1,200 shares@ US$33.120.9% of flowCommon StockSEC:0000950170-24-106949:3
- 1,900 shares@ US$34.041.4% of flowCommon StockSEC:0000950170-24-106949:4
- 16,666 shares@ US$4.353.2% of flowCommon StockSEC:0000950170-24-106949:0
- 100 shares@ US$20.870.0% of flowCommon StockSEC:0000950170-24-096496:1
- 16,667 shares@ US$4.351.6% of flowCommon StockSEC:0000950170-24-096496:2
- 10,476 shares@ US$34.558.2% of flowCommon StockSEC:0000950170-24-096496:3
- 6,191 shares@ US$35.034.9% of flowCommon StockSEC:0000950170-24-096496:4
- 100 shares@ US$24.820.1% of flowCommon StockSEC:0000950170-24-096496:0Canonical exit: 22 Apr 2024 (T+90)
- 17,920 shares0Common StockSEC:0001209191-24-003027:0
- 1,000 shares@ US$9.03Common StockSEC:0001104659-15-086780:0Canonical exit: 22 Mar 2016 (T+90)
- 5,022 shares@ US$5.40Common StockSEC:0001104659-15-081133:0
- 100,000 shares@ US$2.75Common StockSEC:0001209191-11-047733:0
- 10,000 shares@ US$4.05Common StockSEC:0001209191-11-002497:0
- 1,446 shares@ US$3.92Common StockSEC:0001209191-10-060806:0
- 10,000 shares@ US$3.80Common StockSEC:0001209191-10-059049:0
- 17,500 sharesCommon StockSEC:0001209191-10-058461:0
- 10,000 shares@ US$4.76Common StockSEC:0001209191-10-053830:0
- 10,000 shares@ US$3.23Common StockSEC:0001209191-10-049466:0
- 1,447 shares@ US$2.70Common StockSEC:0001209191-10-046384:0
25 of 56 declarations
